The hallmarks of CDKN1C (p57, KIP2) in cancer.

[1]  P. Koehler.  Use of corticosteroids in neuro-oncology. , 1995, Anti-cancer drugs.

[2]  Koehler Pj.  Use of corticosteroids in neuro-oncology. , 1995 .

[3]  S. Elledge,et al.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. , 1995, Genes & development.

[4]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[5]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[6]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[7]  V. Lelièvre,et al.  Switches in the expression and function of PACAP and VIP receptors during phenotypic interconversion in human neuroblastoma cells , 1996, Neuropeptides.

[8]  Y. Fukushima,et al.  An imprinted gene p57KIP2 is mutated in Beckwith–Wiedemann syndrome , 1996, Nature Genetics.

[9]  S. Elledge,et al.  Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. , 1996, Oncogene.

[10]  A. Feinberg,et al.  Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[12]  M. Barbacid,et al.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. , 1997, Genes & development.

[13]  R. Agarwal,et al.  Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. , 1997, Journal of the National Cancer Institute.

[14]  E. Nishida,et al.  Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization , 1998, Nature.

[15]  J. Waschek,et al.  Differential Effects of Peptide Histidine Isoleucine (PHI) and Related Peptides on Stimulation and Suppression of Neuroblastoma Cell Proliferation , 1998, The Journal of Biological Chemistry.

[16]  S. Narumiya,et al.  Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. , 1999, Science.

[17]  W. Reik,et al.  Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation , 1999, Journal of medical genetics.

[18]  E. Sausville,et al.  Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. , 1999, Cancer research.

[19]  S. Okret,et al.  p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. , 1999, Molecular endocrinology.

[20]  Jong-Yeon Shin,et al.  Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer , 2000, Experimental & Molecular Medicine.

[21]  H. S. Kim,et al.  Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. , 2000, Cancer research.

[22]  W. Schulz,et al.  Decreased expression of p57KIP2mRNA in human bladder cancer , 2000, British Journal of Cancer.

[23]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[24]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[25]  D. Dickinson,et al.  Chemopreventive effects of green tea polyphenols correlate with reversible induction of p57 expression. , 2001, Anticancer research.

[26]  K. Wakasa,et al.  Expression of p57/Kip2 Protein in Pancreatic Adenocarcinoma , 2001, Pancreas.

[27]  M. Monden,et al.  Expression of p57/Kip2 Protein in Hepatocellular Carcinoma , 2001, Oncology.

[28]  K. Nakayama,et al.  Increased expression of vascular endothelial growth factor in placentas of p57Kip2 null embryos , 2002, FEBS letters.

[29]  M. Toyota,et al.  Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors , 2002, Oncogene.

[30]  Hirokazu Nagai,et al.  Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. , 2002, Blood.

[31]  S. Okret,et al.  A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells. , 2002, Biochemical and biophysical research communications.

[32]  E. Dicicco-Bloom,et al.  Pituitary Adenylate Cyclase Activating Polypeptide Anti-Mitogenic Signaling in Cerebral Cortical Progenitors Is Regulated by p57Kip2-Dependent CDK2 Activity , 2002, The Journal of Neuroscience.

[33]  T. Osaki,et al.  Induction of p57 is required for cell survival when exposed to green tea polyphenols. , 2002, Anticancer research.

[34]  Yasuo Watanabe,et al.  Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. , 2002, Anticancer research.

[35]  M. Monden,et al.  Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. , 2002, Liver.

[36]  V. Sirri,et al.  Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain , 2003, Oncogene.

[37]  A. Senderowicz.  Small-molecule cyclin-dependent kinase modulators , 2003, Oncogene.

[38]  L. Bladh,et al.  Identification of a functional glucocorticoid response element in the promoter of the cyclin-dependent kinase inhibitor p57Kip2. , 2003, Journal of molecular endocrinology.

[39]  Jia-qing Li,et al.  Loss of p57KIP2 is associated with colorectal carcinogenesis. , 2003, International journal of oncology.

[40]  K. Nakayama,et al.  Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Expression of P57(kip2) and cyslinE proteins in human pancreatic cancer. , 2003, Chinese medical journal.

[42]  K. Nakayama,et al.  p57KIP2 Modulates Stress-activated Signaling by Inhibiting c-Jun NH2-terminal Kinase/Stress-activated Protein Kinase* , 2003, Journal of Biological Chemistry.

[43]  B. Joseph,et al.  p57Kip2 cooperates with Nurr1 in developing dopamine cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  K. Hongo,et al.  Inducible Expression of p57KIP2 Inhibits Glioma Cell Motility and Invasion , 2004, Journal of Neuro-Oncology.

[45]  R. Maione,et al.  MyoD induces the expression of p57Kip2 in cells lacking p21Cip1/Waf1: Overlapping and distinct functions of the two cdk inhibitors , 2004, Journal of cellular physiology.

[46]  H. Nakamine,et al.  Expression of the Components of the Cip/Kip Family in Malignant Lymphoma of the Thyroid , 2004, Pathobiology.

[47]  G. Rosner,et al.  Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  横尾 友隆.  p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus , 2005 .

[49]  W. Schulz,et al.  Multiple mechanisms downregulate CDKN1C in human bladder cancer , 2005, International journal of cancer.

[50]  Julia Tischler,et al.  Negative and Positive Regulation of Gene Expression by Mouse Histone Deacetylase1 , 2006, Molecular and Cellular Biology.

[51]  Laura Mariani,et al.  MicroRNAs modulate the angiogenic properties of HUVECs. , 2006, Blood.

[52]  R. Maione,et al.  p57Kip2 is induced by MyoD through a p73-dependent pathway. , 2006, Journal of molecular biology.

[53]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[54]  V. Gorgoulis,et al.  Downregulation of the KIP family members p27KIP1 and p57KIP2 by SKP2 and the role of methylation in p57KIP2 inactivation in nonsmall cell lung cancer , 2006, International journal of cancer.

[55]  P. S. Larson,et al.  CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer , 2008, BMC Cancer.

[56]  J. Padbury,et al.  Forced expression of the cell cycle inhibitor p57Kip2 in cardiomyocytes attenuates ischemia-reperfusion injury in the mouse heart , 2008, BMC Physiology.

[57]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[58]  B. Joseph,et al.  The cell cycle inhibitor p57Kip2 promotes cell death via the mitochondrial apoptotic pathway , 2007, Cell Death and Differentiation.

[59]  H. Choy,et al.  SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. , 2007, Neoplasia.

[60]  Patricia M. LoRusso,et al.  A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors , 2008, Investigational New Drugs.

[61]  D. Dickinson,et al.  EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells: role of c-Jun N-terminal kinase. , 2007, Toxicology and applied pharmacology.

[62]  W. D. Cress,et al.  Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity , 2007, Oncogene.

[63]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Richard J. Jones,et al.  Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia , 2007, Clinical Cancer Research.

[65]  R. Matusik,et al.  Down-regulation of p57Kip2 induces prostate cancer in the mouse. , 2008, Cancer research.

[66]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[67]  Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a) , 2008, International Urology and Nephrology.

[68]  M. Arkin,et al.  SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples , 2009, Cancer Chemotherapy and Pharmacology.

[69]  James M. Roberts,et al.  CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .

[70]  Significance of p 57 Kip 2 down-regulation in oncogenesis of bladder carcinoma : an immunohistochemical study , 2008 .

[71]  C. Ampe,et al.  Ins and outs of ADF/cofilin activity and regulation. , 2008, European journal of cell biology.

[72]  F. Della Ragione,et al.  Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor. , 2007, Carcinogenesis.

[73]  T. Tsurumi,et al.  Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A. , 2008, Oncology reports.

[74]  Hans Clevers,et al.  Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2 , 2008, EMBO reports.

[75]  E. Medrano,et al.  Different expression patterns of p27KIP1 and p57KIP2 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes , 2009, Journal of cutaneous pathology.

[76]  Jeffrey A Jones,et al.  Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  V. Narry Kim,et al.  Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer , 2009, Nucleic acids research.

[78]  J. Biegel,et al.  Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors , 2009, PloS one.

[79]  V. Gorgoulis,et al.  p 57 KIP 2 : “ Kip ” ing the Cell under Control , 2009 .

[80]  M. Story,et al.  SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting hypoxia inducible factor-1alpha expression. , 2009, International journal of oncology.

[81]  Gian Luca Grazi,et al.  MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality , 2009, Clinical Cancer Research.

[82]  G. Enders,et al.  Chemoprevention of Mouse Intestinal Tumorigenesis by the Cyclin-Dependent Kinase Inhibitor SNS-032 , 2009, Cancer Prevention Research.

[83]  B. Joseph,et al.  The Cdk inhibitor p57Kip2 controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics , 2009, Oncogene.

[84]  E. R. Andersson,et al.  p57Kip2 is a repressor of Mash1 activity and neuronal differentiation in neural stem cells , 2009, Cell Death and Differentiation.

[85]  Zhiwei Wang,et al.  TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. , 2009, Cancer research.

[86]  Iris Barshack,et al.  MiR‐92b and miR‐9/9* Are Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors , 2008, Brain pathology.

[87]  Ryan J. Wagner,et al.  MicroRNA 92b Controls the G1/S Checkpoint Gene p57 in Human Embryonic Stem Cells , 2009, Stem cells.

[88]  L. Miller,et al.  CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells , 2009, PloS one.

[89]  V. Gorgoulis,et al.  p57KIP2: “Kip”ing the Cell under Control , 2009, Molecular Cancer Research.

[90]  M. Story,et al.  The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. , 2009, Lung cancer.

[91]  L. Maeng,et al.  Prognostic significance of O6‐methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B‐cell lymphomas , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[92]  C. Kang,et al.  Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. , 2010, International journal of oncology.

[93]  M. Grever,et al.  A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors , 2012, Investigational New Drugs.

[94]  T. Kinoshita,et al.  Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma. , 2010, Leukemia research.

[95]  K. Nan,et al.  Prognostic significance of co‐expression of nm23 and p57 protein in hepatocellular carcinoma , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[96]  R. George,et al.  CDKN1C (p57KIP2) mRNA expression in human retinoblastomas , 2010, Ophthalmic genetics.

[97]  Muneesh Tewari,et al.  MiR‐221 and MiR‐222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival , 2010, Genes, chromosomes & cancer.

[98]  D. Calvisi,et al.  The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease , 2009, International journal of cancer.

[99]  W. Plunkett,et al.  Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  P. Pu,et al.  MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN , 2010, BMC Cancer.

[101]  S. Perrotta,et al.  p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. , 2011, Carcinogenesis.

[102]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.